In patients with advanced HR+, HER2-negative breast cancer, the combination of endocrine therapy with a CDK4/6 inhibitor is considered the standard of care in first-line therapy, given the ability of this treatment to prolong patients’ PFS [2,3,4,5,6,7,8]. Here, ERBB2 is linked to breast carcinoma.